AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00859196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol (BAY81-2996)
Description: Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
Study NCT00859196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
Study NCT00632229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
Study NCT00632229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
Study NCT00464633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: 1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~* 30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~* 30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours.
Study NCT00306501 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Swallowing Training
Description: Swallowing Training with press of button
Study NCT00746382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast cream
Description: Roflumilast cream 0.5% versus Placebo cream
Study NCT00746382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream
Study NCT02871986 — intervention group
Intervention type: DRUG
Intervention: Routine transdermal oestrogen patch
Description: Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
Study NCT04794777 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Individualised therapy
Description: Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention.
Study NCT04794777 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard salvage therapy
Description: Standard salvage radiotherapy
Study NCT02559284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A postoperative care after ethmoid sinus surgery
Description: A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing).
Study NCT02559284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A postoperative care after ethmoid sinus surgery
Description: A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing).
Study NCT02578147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mighty Girls
Study NCT02578147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Game Girls
Study NCT00656448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procrit
Description: 40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
Study NCT04964180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin suppository
Description: two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
Study NCT04964180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: 200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
Study NCT01808456 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza trivalent inactive vaccine
Description: one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
Study NCT01808456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza trivalent inactive vaccine high dose
Description: one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
Study NCT04071717 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
Study NCT04071717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIRS neurofeedback
Description: Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
Study NCT04071717 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham NIRS neurofeedback
Description: Sham NIRS neurofeedback
Study NCT01981408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY2801653
Description: Administered orally
Study NCT02877407 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: patient who undergo laparoscopic/robotic-assisted hysteropexy
Study NCT02877407 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: patient who undergo vaginal hysterectomy
Study NCT00646048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriVascular Stent-Graft System
Description: TriVascular Stent-Graft System
Study NCT01547611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customary treatment
Description: The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
Study NCT01547611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured behavioural medicine program
Description: The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
Study NCT00863278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser treatment
Description: On one side of the face according to Arm placement.
Study NCT00863278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kligman's Trio
Description: The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Study NCT00432172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03968393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulant (NOAC)
Description: Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
Study NCT00700479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldosterone
Description: 4 hour infusion
Study NCT00700479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low or high sodium diet
Study NCT00700479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low or high sodium diet
Study NCT00700479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02756286 — intervention group
Intervention type: OTHER
Intervention: NAT electroencephalography (EEG) test
Description: Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaliproden (SR57746A)
Description: oral administration
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: IV administration
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administration
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: IV administration
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: IV administration
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: IV administration
Study NCT00305188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV administration
Study NCT00888173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib Alaninate
Description: Given PO
Study NCT00888173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04514861 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless Lumee Oxygen Platform
Description: The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
Study NCT01113255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bench-evaluation, of three ventilators
Description: to select in-VITRO the most appropriate ventilator for a given pathology.
Study NCT02939911 — intervention group
Intervention type: DEVICE
Intervention: Residual neuromuscular blockade measurement
Description: Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
Study NCT02007096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transabdominal Plane Block
Description: 0.25% bupivacaine injection in 6 different locations in abdomen. Weight \<100kg: 50ml total; weight >100kg: 60ml total
Study NCT02007096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non Transabdominal Plane Block
Description: Saline injection in 6 different locations in abdomen. Weight \<100kg: 50ml; weight >100kg: 60ml
Study NCT04124809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser assisted collapse
Description: Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
Study NCT02233686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN-D0501
Study NCT02233686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01752335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Braquial ecography
Description: At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
Study NCT00630838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding.
Study NCT00630838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
Study NCT05313971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self knowledge course
Description: The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
Study NCT04551547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 300SU/0.5ml
Study NCT04551547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml
Study NCT04551547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0,28
Description: The placebo contains no active ingredient and manufactured by Sinovac Research \& Development Co., Ltd.
Study NCT03010215 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Distal Metatarsal Minimally invasive Osteotomy (DMMO)
Description: Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.~In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer.
Study NCT02070003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Physician Guided Opioid Weaning
Study NCT00872820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance- and commitment-based behavioral therapy
Description: 12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
Study NCT00872820 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
Study NCT04537624 — intervention group
Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study NCT04201262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
Study NCT03459755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise.
Study NCT00794716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
Study NCT01051895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high risk HPV DNA testing
Description: Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
Study NCT01051895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Routine colposcopy
Description: Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
Study NCT03003325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOP2014
Description: AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
Study NCT03003325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomies
Description: According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT\< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.